US EditionInsulet earns insulin patch pump patent victory against EOFlow
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Insulet earns insulin patch pump patent victory against EOFlow
The Insulet Omnipod 5 (left) and the EOFlow EOPatch (right), just acquired by Medtronic. A judge has issued a permanent injunction, signaling an Insulet (Nasdaq:PODD) victory in a trade secret case against EOFlow. The permanent injunction highlights the successful defense of Insulet’s intellectual property. Subsequently, the damages award was reduced from $452 million to $60 million at Insulet’s election. The company wanted the permanent injunct…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
